Medical use of cannabis for dry eye disease

(November 2018)

Background

The clinical value of cannabis in alleviating the symptoms of dry eye disease (DED) is limited at this time due to a lack of clinical evidence.

The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of DED or its associated pain symptoms, due to its undesirable side-effects, including dry eye symptoms if smoked, and the absence of scientific evidence showing any beneficial effect at this time.

Other evidence-based, less harmful treatment modalities are available for DED and its associated symptoms.

Access Details

Read the full position statement and recommendations from the Canadian Ophthalmological Society (COS).

Related Resources

Immediate Sequential Bilateral Cataract Surgery (ISBCS) COVID-19 Considerations

December, 2020 This document, prepared by ACUPO and endorsed by...

More Info

CMA Physician Wellness Hub

As a physician, when you’re well, everyone benefits. Healthy and...

More Info

OICS Guidelines for the Cleaning and Sterilization of Intraocular Surgical Instruments

December, 2020 Guidelines for the Cleaning and Sterilization of Intraocular...

More Info

Half of all #glaucoma patients are unaware that they have the condition. That’s why eye exams are so important! bit.ly/12lZigR #glaucoma #eyehealth #ophthalmology #GlaucomaAwarenessMonth

Yesterday from Can Ophthal Society's Twitter via Hootsuite Inc.

Can Ophthal Society's Twitter via Twitter Web Client